EUCTR2011-006043-30-NL进行中（未招募）不适用
An open-label, multiple-dose, two-treatment period study to evaluate the effect of oral BAF312 on the pharmacokinetices and pharmacodynamics of a monophasic oral contraceptive in healthy female volunteers
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. written IC
- •2. healthy females of childbearing potential 18-40 years + in good health as determined by past medical history, physical examination, vital signs, ECG, 24 h Holter and lab tests, PAP smear, gynecological exam. and transvaginal ultrasound before dosing in period 1
- •3. Stable regimen of monophasic OC containing EE (30 microgram)/LVG (150 microgram) as for at least three cycles prior to dosing in period 1 and willing to undergo synchronization of at least one cycle until day -7. Any subject not taking any OC or taking another brand of monophasic OC should be willing to take monophasic OC containing EE 30 microgram and LVG 150 microgram for at least three cycles during synchronization until day -7.Willing to continue OC until at least 30 d after study completion
- •4. negative pregnancy test results at screening and baseline 1
- •5. willing to use additional, non-hormonal contraception from screening until 30 days after study completion.
- •6. willing to undergo genotyping screening prior to baseline 1, must be CYP2C9 WT
- •7. willing to abstain from strenuous and/or unaccustomed physical exercise for 7 d before dosing with OC at D1 until after study completion evaluation. At screening and baseline 1, vital signs (BP and pulse rate) will be assessed in supine position after the subject has rested for at least 3 min, and again when required after 3 min in the standing pos. Investigator can be guided by: oral body temp 35-37.5°C, systolic BP 90-140 mm Hg, diastolic BP 50-90 mm Hg, pulse rate 50-90 bpm. BP and pulse after 3 min standing no more than 20 mm Hg drop systolic or 10 mm Hg drop diastolic and increase in heart rate >20 bpm (compared to sitting) associated with clin. manifestation of postural hypotension.
- •8. weight of at least 50 kg, BMI in the range of 18-30 kg/m2
- •9. abilitity to communicate well, understand and comply
- •Other protocol defined inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. use of other investigational drugs at the time of baseline 1, or within 30 days or half-lives of baseline1, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations.
- •2. Hypersensitivity to study drug or drugs of similar chemical class. Bad tolerance to OCs during synchronization period
- •3. any contra-indication to OCs with EE/LVG
- •4. females who do not have had 3 consecutive menstrual cycles post partum
- •5. breast-feeding females or have stopped breast-feeding less than 6 mths before initial dosing
- •6. history of irregular menses or pregnancy while on OCs
- •7. current or medical history of any of following CV findings: 2nd and 3rd degree AV-block, clin. significant ECG findings, supraventricular arrhythmias, arrhythmias (e.g. Brugada syndrome, Long QT syndrome, WPW syndrome, LGL syndrome, ARVD etc.), heart failure or left ventricular dysfunction
- •8. history of malignancy of any organ system within 5 past years (other than localized basal cell carcinoma of skin)
- •9. smokers
- •10. use of any prescription drugs, herbal supplements within 4 wks prior to initial dosing (i.d.) (excepts monophasic OCs), and/or OTC medication, dietary supplements withing 2 wks prior i.d.
- •11. Donation or loss of 400 ml or more blood within 8 wks prior i.d.
- •12. Plasma donation within 7 d prior i.d.
- •13. Significant illness not resolved within 2 wks prior i.d. that may impact ADME of drugs or safety of subject
- •14. Recent (within last 3 y ) +/or recurrent history of autonomic dysfunction, acute or chronic bronchospastic disease (e.g. asthma and COPD) (15.)
- •16. medical history of any arterial disease or embolic conditions which predispose to clotting disorders or other risk factors with OC use
- •17. current or history of mammary or endometrial carcinoma
- •18. depot estrogens or progesterione injection within 10 mths prior baseline 1
- •19. surgical or medical condition which might significantly alter ADME of drugs or jeopardize subject: history of -inflamatory bowel disease, -ulcers, -GI or rectal bleeding, -major GI tract surgery, -pancreatic injury or pancreatitis - livery disease or liver injury and presence of abnormal liver function tests (applying criteria please see protocol) -impaired renal function as indicated (see protocol), evidence of urinary obstruction of difficulty in voiding
- •20. history of immunodeficiency diseases
- •21. positive HBsAg or Hep C test result
- •22. history of drug or alcohol abuse within 12 mths prior i.d
- •23. score 4 or 5 on the suicidal ideation items or any yes on the suicidal behavior item that is related to suicidal behaviour occuring during the last 2 years
- •Other protocol defined exclusion criteria may apply
研究者
相似试验
已完成
不适用
An open-label, multiple-dose, two-treatment period study to evaluate the effect of oral BAF312 on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in healthy female volunteers.MS10003816Multiple SclerosisNL-OMON37415ovartis24
已完成
不适用
An open-label, multiple-dose, sequential, 2 treatment period study to evaluate the effect of QBW251 on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in pre-menopausal healthy female volunteersCFmucoviscidosis1004078910013326NL-OMON40637ovartis47
进行中（未招募）
不适用
A two-staged, open label, single dose, two period, two-sequence,crossover study to compare the bioavailability of 2 mg GlycopyrroniumBromide from a new oral solution (2 mg/5 ml) (Test Product) with thatof 2 mg Glycopyrronium Bromide from Cuvposa (1 mg/5 ml) Solution(Reference product) in at least 36 healthy male and female subjectsunder fasting conditions.Sialorrhoea (chronic pathological drooling)EUCTR2013-002557-30-Outside-EU/EEAProveca Ltd36
已完成
不适用
Study to evaluate the safety and pharmacokinetics after co-administration of UIC201601 and UIC201602Endocrine, nutritional and metabolic diseasesKCT0007411Korea United Pharm40
进行中（未招募）
1 期
Clinical trial in Healthy Volunteers to test Valsartan PharmacokineticsHypertensionEUCTR2016-004323-23-Outside-EU/EEAovartis86